Loading…
Claritev Corporation is projected to rise to $28.58 by 2027, a +24% move from its current price of $23.07. CTEV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $21.16 | $23.11 | $25.23 | +0.15% |
| May 30 | $20.43 | $23.14 | $26.21 | +0.31% |
| May 31 | $19.90 | $23.18 | $26.99 | +0.46% |
| Jun 1 | $19.47 | $23.21 | $27.68 | +0.61% |
| Jun 2 | $19.09 | $23.25 | $28.30 | +0.77% |
| Jun 3 | $18.77 | $23.28 | $28.88 | +0.92% |
| Jun 4 | $18.47 | $23.32 | $29.43 | +1.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.47 | $23.32 | $29.43 | +1.08% |
| Week 2 | $16.96 | $23.57 | $32.76 | +2.16% |
| Week 3 | $15.92 | $23.82 | $35.66 | +3.26% |
| Week 4 | $15.11 | $24.08 | $38.36 | +4.37% |
| Week 5 | $14.46 | $24.34 | $40.96 | +5.50% |
| Week 6 | $13.91 | $24.60 | $43.51 | +6.63% |
| Week 7 | $13.43 | $24.86 | $46.04 | +7.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Claritev Corporation is a healthcare-focused data analytics and technology-enabled solutions provider serving the United States health industry. Its offerings cover end-to-end cost management, payment, and revenue integrity services across claims intelligence, network solutions, and payment integrity. These include reference-based pricing, negotiation services, surprise bill services, and Vistara; primary networks, complementary networks, and network build and management; as well as clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services.
It also provides data and analytics tools such as PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services.
The company serves commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators, along with national and regional insurers, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies, and other entities involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.
Claritev Corporation (CTEV) is currently priced at $21.67 and sits in the healthcare data analytics and cost-management space in the United States. It trades with a market capitalization of $369.43M and is ranked 3308 by market size among peers. The 2026 forecast shows an average price of $21.67 with a neutral stance and no predicted return on investment for that year.
The longer horizon from 2027 to 2050 is bullish, with rising averages and substantial upside potential, culminating in a 2050 average of $204.90 and an estimated ROI of 845.5, signaling a strong growth trajectory while acknowledging inherent uncertainty.
A major floor 72.2% below — a decisive break under it would weaken the trend.
The nearest floor, 39.9% below — buyers have tended to step in here.
The nearest ceiling, 28.5% above — a clean break opens room to run.
A major ceiling 64.6% above — clearing it would confirm fresh momentum.
Key CTEV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTEV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.26 | Buy | $21.94 | Buy |
| MA 10 | $20.88 | Buy | $21.94 | Buy |
| MA 20 | $23.43 | Sell | $22.18 | Buy |
| MA 50 | $20.28 | Buy | $21.96 | Buy |
| MA 100 | $22.07 | Buy | $25.01 | Sell |
| MA 200 | $38.76 | Sell | $29.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.06 | Neutral |
| Stoch RSI (14) | 49.70 | Neutral |
| CCI (20) | -8.05 | Neutral |
| Williams %R (14) | -41.70 | Info |
| MACD (12,26,9) | -0.32 | Sell |
| ROC (12) | -14.56 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 58.30 | Neutral |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 68.77 | Neutral |
| Momentum (10) | -5.46 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 23.57 | Sell |
| ADX (14) | 18.96 | Neutral |
| ATR (14) | 1.92 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50. The 50-day simple moving average is $20.07 and the 200-day simple moving average is $39.10, indicating near-term momentum sits between short and long-term trend lines. Support is positioned at $13.87 and resistance at $29.65, framing a near-term range that reflects mixed momentum.
The 30-day range spans from $11.74 to $39.99, underscoring notable volatility in the recent window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.47 | $23.07 | $37.46 | 0% | Neutral | |
| $20.57 | $28.58 | $42.98 | +24% | Bullish | |
| $20.92 | $30.85 | $49.32 | +34% | Bullish | |
| $22.23 | $34.51 | $57.84 | +50% | Bullish | |
| $23.75 | $38.63 | $67.35 | +67% | Bullish | |
| $33.16 | $56.35 | $101.63 | +144% | Bullish | |
| $38.41 | $68.08 | $126.55 | +195% | Bullish | |
| $40.02 | $73.86 | $141.06 | +220% | Bullish | |
| $40.07 | $76.91 | $150.57 | +233% | Bullish | |
| $32.80 | $65.44 | $131.07 | +184% | Bullish | |
| $64.73 | $143.83 | $316.37 | +523% | Bullish | |
| $119.35 | $265.22 | $610.00 | +10.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $13.47 | $23.07 | $27.59 | +0.00% |
| June 2026 | $21.15 | $25.37 | $31.53 | +9.96% |
| July 2026 | $21.74 | $26.52 | $33.80 | +4.54% |
| August 2026 | $21.36 | $26.40 | $34.30 | -0.46% |
| September 2026 | $22.21 | $27.76 | $36.63 | +5.15% |
| October 2026 | $23.25 | $29.35 | $39.28 | +5.75% |
| November 2026 | $22.34 | $28.46 | $38.55 | -3.03% |
| December 2026 | $21.27 | $27.34 | $37.46 | -3.95% |
Click any year to see its month-by-month CTEV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CTEV is projected to trade between $13.47 and $37.46, averaging $23.07 — a potential gain of 0% from today's $23.07. A consolidation phase looks the most probable path here.
Claritev Corporation's 2027 outlook centres on $28.58, within a $20.57 to $42.98 range. That is up +24% on the projected 2026 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2028, CTEV could reach as high as $49.32, with a base case around $30.85 and support toward $20.92 — roughly +34% from $23.07. Buyers look set to stay in control over this stretch.
Expect CTEV to range from $22.23 to $57.84 through 2029. The $34.51 average target implies a +50% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The CTEV price prediction for 2030 points to an average of $38.63 (low $23.75, high $67.35) — a potential gain of +67% on today's $23.07. Buyers look set to stay in control over this stretch.
In 2031, CTEV is projected to trade between $33.16 and $101.63, averaging $56.35 — a potential gain of +144% from today's $23.07. That is up +46% on the projected 2030 average. Momentum favours further upside here.
Claritev Corporation's 2032 outlook centres on $68.08, within a $38.41 to $126.55 range. That is up +21% on the projected 2031 average. That marks a +195% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CTEV could reach as high as $141.06, with a base case around $73.86 and support toward $40.02 — roughly +220% from $23.07. Momentum favours further upside here.
Expect CTEV to range from $40.07 to $150.57 through 2034. The $76.91 average target implies a +233% move from current prices. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CTEV price prediction for 2035 points to an average of $65.44 (low $32.80, high $131.07) — a potential gain of +184% on today's $23.07. Momentum favours further upside here.
In 2040, CTEV is projected to trade between $64.73 and $316.37, averaging $143.83 — a potential gain of +523% from today's $23.07. That is up +120% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Claritev Corporation's 2050 outlook centres on $265.22, within a $119.35 to $610.00 range. That is up +84% on the projected 2040 average. That marks a +10.5x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CTEV today (≈ 43.346337 CTEV) could be worth
$11,496.16
+$10,496.16 (+1050%) by 2050 · US Dollar
Based on the average projected CTEV price of $265.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTEVwould be worth at today's price.
$1,000 invested in CTEV on May 27, 2025 (≈ 36.496351 CTEV) would be worth
$841.97
-$158.03 (-15.8%) today · 0.84× · US Dollar
Based on a CTEV entry price of $27.4 vs. today's $23.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.24 | $1,086.16 | +8.6% |
| 1 month ago | $24.22 | $952.52 | -4.7% |
| 3 months ago | $14.17 | $1,628.09 | +62.8% |
| 6 months ago | $54.07 | $426.67 | -57.3% |
| 1 year ago | $27.4 | $841.97 | -15.8% |
| All time (5.0y) ago | $339.2 | $68.01 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTEV forecast.
Our base-case forecast reaches $46.00 around 2031.
Implied market cap at $46.00: $784.2M
The multi-year forecast shows a bullish transition beginning in 2027 as the average price climbs from $26.49 (2027) to higher levels in following years. By 2030 the forecast average is $33.42 with a 54.2 RO I% and bullish sentiment, rising further toward 2040 where the average is $115.67 and the ROI reaches 433.8. The estimate for 2050 shows an average of $204.90 with an ROI of 845.5 and bullish sentiment, illustrating a substantial long-term upside potential.
The sequence from 2027 onward reflects a consistent upward trajectory in the average price, supported by the bullish sentiment, while each year remains an estimate rather than a guarantee. Key intermediate years include 2028 (avg $27.56, ROI 27.2), 2029 (avg $30.75, ROI 41.9), and 2031–2035 showing continued growth with higher average prices. Potential risks include market volatility and execution risk in healthcare data analytics and cost-management offerings, which could temper upside.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $33.42 with a min of $20.54 and a max of $58.30. The forecasted ROI is 54.2 and sentiment is BULLISH.
Forecasts indicate a bullish sentiment from 2027 onward, with the average rising from $26.49 (2027) to $204.90 (2050) and a maximum implied price of $471.26 in 2050. The implied ROI reaches 845.5, though these are estimates and not guarantees.
Yes. The 2040 forecast lists an average of $115.67 with a min of $52.05 and a max of $254.47, and the 2050 forecast shows an average of $204.90 with a max of $471.26, indicating potential to exceed $100 under certain conditions.
Current price is $21.67 and market capitalization is $369.43M.
The 30-day range is $11.74 to $39.99, with support at $13.87 and resistance at $29.65. The annualized volatility is 200%.
Claritev Corporation Community Discussion
0Share your Claritev Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.